Novartis Plea For Glivec Rejected

GlivecFull.jpg

The Supreme Court on April 1 dismissed Swiss pharmaceutical chain Novartis AG's petition seeking patent protection for its anti-cancer drug, Glivec (Imatinib mesylate). The court has also dismissed plea of the multinational pharma company to restrain Indian drug firms from manufacturing generic drugs. The apex court bench of Justices Aftab Alam and … [Read more...]